Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer

Mark W Burns
Eric S Kim
Wilmot Cancer Center, University of Rochester, Rochester, NY, USA

Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancers that are generally insensitive to chemotherapy. An estimated 3%–7% of NSCLC patients harbor tumors containing anaplastic lymphoma kinase (ALK) gene rearrangement as an oncogenic driver. Subsequent development of the first-generation tyrosine kinase inhibitor crizotinib demonstrated substantial initial ALK+–tumor regression, yet ultimately displayed resistance in treated patients. The recently approved tyrosine kinase inhibitor ceritinib has been shown to be an effective antitumor agent against crizotinib-naïve and -resistant ALK+–NSCLC patients. In this review, we will provide an overview of biology and management of ALK+–NSCLC with a special focus on clinical development of ceritinib.

Keywords: ceritinib, anaplastic lymphoma kinase, non-small-cell lung cancer

Anaplastic lymphoma kinase and its role in non-small-cell lung cancer

The anaplastic lymphoma kinase (ALK) is a type-I transmembrane tyrosine kinase belonging to the insulin receptor superfamily and is hypothesized to be active in the early development and maintenance of the central and peripheral nervous systems. The 729 kbp gene is located on the p-arm of human chromosome 2 and encodes a functioning 220 kDa transmembrane receptor, containing an extracellular ligand-binding domain, a single-pass membrane spanning domain, and a catalytic intracellular kinase domain. A significant degree of ALK mRNA expression throughout developing nervous tissues of both embryonic mice and humans has led to the hypothesis that the ALK gene product is involved in the maturation and maintenance of early nervous tissues. It has been generally understood that, under normal psychological conditions, binding of a currently unknown mammalian ligand to the extracellular domain induces dimerization of ALK, allowing autophosphorylation and subsequent activation of the intracellular kinase domain. The kinase propagates downstream pathways required for cell growth and passage through the cell cycle. Activated ALK proteins are involved in numerous overlapping signaling pathways, specifically the PLC-γ and Ras/ERK1/2 pathways that participate in cell proliferation and the JAK/STAT and PI3K/AKT pathways that propagate cell survival. The intensity of ALK mRNA and protein expression subsequently diminishes in mammals after birth,
reaching a minimum level approximately 3 weeks after birth and maintained at low levels throughout normal adulthood.

Considering that normal ALK has very little (if any) activity in mature human tissues, the detection of active ALK domains in tumor samples of non-small-cell lung cancer (NSCLC) patients implicates the oncogenic nature of activated ALK pathways in this subset of metastatic cancers. Despite a vast majority of NSCLCs being associated with mutations induced through tobacco use or exposure, ALK+NSCLC is most prevalent in nonsmokers. Genetic anomalies within the ALK gene through rearrangement, amplification, or mutation produce constitutively active ALK fusion protein domains responsible for the pathogenesis of ALK+NSCLCs. These ALK fusion genes are currently identified in NSCLC patients through tests such as fluorescence in situ hybridization (FISH), immunohistochemistry assay, and reverse transcription-polymerase chain reaction. Furthermore, advancements in next-generation genomic sequencing now permit more rapid and reliable detection of ALK+ tumors.

Abnormalities observed in ALK+NSCLCs are mainly the result of gene rearrangement. Inversions in the p-arm of chromosome 2 lead to the conjunction of the echinoderm microtubule-associated protein-like 4 (EML4) and ALK genes, producing an active fusion protein that is detected in numerous carcinomas. Translocations of the ALK gene have been discovered in numerous carcinomas, including neuroblastomas, anaplastic lymphomas, and inflammatory myofibroblastic tumors, but the first instance of EML4–ALK translocation was described in 2007 using tumor cell samples from a 62-year-old NSCLC patient, in which the fusion gene induced the activation of the intracellular kinase domain of ALK. Meta-analyses reveal that the EML4–ALK fusion gene is correlated with younger, nonsmoking female populations. All EML4–ALK fusion genes observed in NSCLCs contain exons 20–29 of ALK (encoding the intracellular domain) and eight different EML4 exons, all of which activate the downstream signals of Ras/ERK1/2 and JAK/STAT. It has been suggested that the prevalence of both the ALK mRNA and protein (specifically, the intracellular kinase domain) in NSCLC patients is the product of the EML4–ALK translocation and not the intact ALK gene, which is consistent with the view that active EML4–ALK is an oncogenic driver for the growth of tumors in patients harboring this ALK translocation. The EML4–ALK fusion protein undergoes auto-phosphorylation of its intracellular ALK kinase domain, constitutively activating the Ras signaling pathway that ultimately results in uncontrolled cell growth.

**First-generation ALK inhibitor: profile of crizotinib**

Because the ALK kinase is required for oncogenic activity in this subdivision of NSCLCs, tyrosine kinase inhibitors (TKIs) have been developed as antitumor therapies. Crizotinib (formerly known as PF-02341066 and marketed as Xalkori®, Pfizer), while originally synthesized as a c-MET inhibitor, demonstrated remarkable antitumor activity in patients harboring ALK+ tumors. As a TKI, crizotinib acts to competitively inhibit the ATP-binding domain of ALK, effectively preventing its downstream mechanisms of proliferation/replication while simultaneously inducing apoptosis. An initial phase I clinical trial investigating crizotinib resulted in a response rate of 57% and a 6-month progression free survival (PFS) rate of 72% with only mild toxicities. These clinical results were deemed more favorable than response rates observed in NSCLC patients treated solely with platinum-based chemotherapies. The Food and Drug Administration approved crizotinib for the treatment of ALK+ NSCLC in August 2011. A recently published PROFILE 1014 Phase III trial compared the efficacy and safety profile of crizotinib vs chemotherapy (pemetrexed-cisplatin or pemetrexed-carboplatin) in previously untreated patients with advanced ALK+ NSCLC, and found that the crizotinib arm showed both improved PFS and overall response rate (ORR) (10.9 months and 74%, respectively) over the standard chemotherapy arm (7.0 months and 45%, respectively). Patients receiving crizotinib also self-reported more improvements in cancer-related pain and a better quality of life than patients receiving standard chemotherapy. Thus, crizotinib has become the standard of care in patients harboring ALK+ tumors.

Despite its initial success in the treatment of ALK+NSCLC, resistance to crizotinib develops in patients after approximately 10 months of treatment. Numerous factors likely contribute to the development of crizotinib resistance. Missense mutations in the kinase domain of the fusion protein that result in either diminished crizotinib binding or increased ATP binding is one such potential mechanism of resistance. Currently, seven distinct acquired resistance mutations have been identified in crizotinib-resistant tumors: the two most common being the gatekeeper mutations L1196M and G1269A and the remaining five mutations L1171T, L1152R, G1290A, G1202R, and S1206Y. Multiple, nonoverlapping resistance mutations of the ALK kinase domain have been observed in some patients. Others expressed mechanisms that activated downstream signaling pathways of ALK.
without mutating the kinase itself, and a small number of patients simply failed to respond to crizotinib in the absence of any resistance mutations. In vitro analysis also demonstrates that the multiple variants of the \textit{EML4–ALK} fusion protein may exhibit variable sensitivities to TKIs, consistent with the clinical range of responses to crizotinib treatment. Therefore, while some secondary mutations may exhibit continued responses to crizotinib, other mutations may confer resistance to the TKI and ultimately lead to the progression of metastatic \textit{ALK}+ tumors.

While crizotinib demonstrates substantial antitumor activity in systemic disease, it appears to be less efficacious in targeting CNS metastasis. This could be due to the fact that crizotinib has a poor ability to penetrate the blood–brain barrier. A case report of a 29-year-old patient with \textit{ALK}+NSCLC demonstrated cerebrospinal crizotinib concentration of only 0.616 ng/mL, compared to its systemic serum concentration of 237 ng/mL. This patient exhibited adequate control of his intrathoracic disease when he developed new progressive disease in his brain. Other possible explanations concerning the discrepancy between systemic and CNS crizotinib efficacy, including the development of genetically distinct tumors in the brain that are unaffected by crizotinib and induced secondary mutations in the \textit{ALK} kinase domain within brain parenchyma that confer resistance to TKIs such as crizotinib, have been suggested.

With an approximate rate of CNS metastases in NSCLC patients at 30%, a novel and improved method for delivering antitumor agents through the blood–brain barrier into the cerebrospinal fluid is of importance for tumor suppression in \textit{ALK}+NSCLC patients.

\section*{Chemistry and pharmacology of ceritinib}
Ceritinib (formerly known as LDK378 and marketed as Zykadia™, synthesized from the compound TAE684 by Novartis Pharmaceuticals) is a small, orally administered \textit{ALK} inhibitor prescribed to patients harboring \textit{ALK}+NSCLC that has become resistant to crizotinib therapy. The synthesized molecule has a formula \text{C}_{23}\text{H}_{28}\text{CIN}_{2}\text{O}_{4}\text{S}, an International Union of Pure and Applied Chemistry (IUPAC) name 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, and a molecular weight 557.22 g/mol (Figure 1). Molecular ceritinib has the capacity to accept seven hydrogen bonds and can donate three hydrogen atoms for hydrogen bonding, while also maintaining nine rotatable bonds in physiological conditions. Ceritinib acts as a powerful inhibitor of \textit{ALK}, yet does not demonstrate c-MET inhibition as does its predecessor crizotinib.

Molecular docking simulations of the reported crystal structure of ceritinib have revealed the mechanism by which the molecule interacts with the kinase domain of \textit{ALK}. Acting as a ligand, ceritinib binds via hydrogen bonds with amino acids of the kinase’s hinge area through both the amino nitrogen atoms and the central pyrimidine ring of the inhibitor. The ligand-active site interaction is further stabilized by a salt bridge formed between the terminal piperidine of the inhibitor with Glu1210 of the kinase domain. While molecular ceritinib contains almost double the amount of rotatable bonds compared to crizotinib (ceritinib maintains nine, crizotinib maintains five), the former exhibits potency toward \textit{ALK} 20-fold higher than the latter.

Ceritinib has exhibited cellular specificity to tumors harboring the \textit{ALK} translocated gene through assays determining 50% of maximal inhibition of tumor cell proliferation (GI50 assays) in multiple tumor samples expressing various oncogenic drivers. Ceritinib demonstrated potency in two \textit{ALK}+NSCLC cell lines (H3112 and H2228), but failed to show significant GI50s in tumor cells expressing the other oncogenic drivers EGFR, HER2, KRAS, or PI3K. These findings highlight the specificity of ceritinib in targeting \textit{ALK}+NSCLC cells.

Ceritinib specifically binds to the intracellular kinase domain of the \textit{EML4–ALK} fusion protein, inhibiting its phosphorylation and subsequent activation of its downstream pathways. This mechanism of kinase inhibition involves competitive binding in the fusion kinase domain, preventing induced structural changes that result in activated downstream pathways involved in cell growth and proliferation. By selectively inhibiting this oncogenic process at the initial step of irregular \textit{ALK} activation, ceritinib exhibits...
significant antitumor activity in NSCLC patients harboring ALK translocations. Figure 2 represents a schematic diagram of ceritinib inhibiting phosphorylation of the EML4–ALK kinase and deactivating downstream growth pathways.

Ceritinib maintains a remarkable pharmacokinetic profile in mammals with only mild to few severe side effects in human patients. The maximum tolerated dose (MTD) of ceritinib is 750 mg on an empty stomach, with antitumor results observable in patients treated with 400 mg daily. The maximum human plasma concentration of ceritinib is realized 4–6 hours after receiving the MTD.33

Clinical profile of ceritinib
Ceritinib has demonstrated significant activity in crizotinib-naïve ALK+–NSCLC models. In vitro enzymatic assays reveal that ceritinib is more potent than crizotinib at inhibiting the oncogenic ALK fusion protein.32 Ceritinib also inhibits the phosphorylation of both the ALK fusion protein and the downstream signaling pathways ERK and PI3K/AKT at much lower doses than crizotinib.32 In vivo H2228 xenograft models demonstrated the long-lasting antitumor properties of ceritinib. Tumor-bearing animals harboring ALK+ tumors were treated with either crizotinib (100 mg/kg) or ceritinib (25–50 mg/kg) daily for 2 weeks, with the latter experiencing both stronger antitumor suppression and longer durations of responses than the former.32 Additional assays demonstrated that ceritinib potently inhibited cell proliferation in cell lines with one of four resistance mutations in EML4–ALK amino acid sequencing (L1196M, G1269A, I1171T, and S1206Y), yet the five EML4–ALK resistance mutants exhibiting one of five amino acid sequence mutations (C1156Y, L1152R, F1174C, G1202R, and 1151T) demonstrated insignificant suppression of growth (albeit with stronger antitumor activity than the same mutant lines treated with crizotinib). From a structural basis of ligand-kinase domain docking, variation in ceritinib efficacy can be explained by the structural change in the kinase’s active site via point mutation. As previously mentioned, the mutations L1196M and G1269A confer resistance to crizotinib but remain sensitive to ceritinib – changes that result in steric interference of crizotinib with the EML4–ALK catalytic domain but do not affect ceritinib binding.32 However, the G1202R mutation results in significant steric hindrance in the active site, which disallows binding of both ceritinib and crizotinib. While currently unknown in their effects on TKI inhibition, the resistance mutations C1156Y, L1152R, F1174C, and 1151T have been predicted to either alter that conformation of the entire kinase or decrease the Km of ceritinib and crizotinib – both possibilities significantly impacting the TKI ability to act as an ATP-competitive agent.32 Thus, ceritinib shows efficacy in tumor cells harboring the common crizotinib-induced resistance mutations, with less impressive results in treating tumors harboring the rarer crizotinib-induced resistance mutations.

In ASCEND-1, a Phase I study investigating ceritinib’s safety and efficacy in ALK+-NSCLC patients, a total of 246 ALK+-NSCLC patients were treated with ceritinib at

Figure 2 Inappropriate activation of the ALK pathway results in uncontrolled tumor growth and proliferation.
Note: Ceritinib acts to inhibit phosphorylation of the EML4–ALK kinase domain, deactivating downstream growth pathways and inhibiting tumor proliferation.
Abbreviations: ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4.
the established maximal tolerated dose of 750 mg/daily.\textsuperscript{8,34} A total of 163 (66%) patients had received prior crizotinib and 83 (34%) patients were ALK inhibitor-naïve. The ORR was 58.5%. Among 163 patients previously treated with crizotinib, an ORR of 54.6% as well as a PFS of 6.9 months was achieved. Among the remaining 83 patients naïve to crizotinib treatment, an ORR of 66.3% was achieved. At the time of data cutoff, a median PFS could not be estimated for crizotinib-naïve patients.\textsuperscript{34} This study concluded that ceritinib at 750 mg/day demonstrated potent antitumor activity in \textit{ALK}+NSCLC regardless of previous therapy status.

A subgroup analysis between Asian and Caucasian patients (82 and 156 patients, respectively) in the ASCEND-1 sought to determine differences in efficacy and adverse reactions among the two distinct populations.\textsuperscript{35} Data from 173 patients demonstrated ORRs of 69% in Asian patients and 57% in Caucasian patients. Median durations of responses in the Asian and Caucasian patients were 10.1 months and 6.9 months, respectively.\textsuperscript{35} Observable variances in ceritinib treatment for these two populations could not be explained by previous ALK inhibitor therapies.

Adverse reaction data (Table 1) collected from 255 \textit{ALK}+NSCLC patients treated with 750 mg daily ceritinib were mainly gastrointestinal, manifested by diarrhea, vomiting, constipation, nausea, and abdominal pain.\textsuperscript{8} Additional serious side effects include hypophosphatemia, hyperglycemia, anemia, elevated liver and pancreatic enzymes, interstitial lung disease, and QT interval prolongation.\textsuperscript{8,33} These adverse events are often reversible after discontinuation of ceritinib treatment.

A total of 19 crizotinib-resistant NSCLC patients underwent tumor biopsy prior to beginning ceritinib treatment. Biopsies from all 19 patients tested positive for \textit{ALK} rearrangement through FISH: two of the 19 patients exhibited \textit{ALK} amplification, five patients exhibited secondary resistance mutations in the tyrosine kinase domain of the \textit{EML4–ALK} fusion protein, and the remaining 12 patients solely exhibited the original oncogenic rearrangement of \textit{ALK}.\textsuperscript{8} Treatment of these cases with the daily maximum dosage of ceritinib resulted in notable antitumor activity in all 19 patients. Significant responses were observed in six of the seven patients harboring either \textit{ALK} amplification or resistance mutations as well as in seven of the 12 patients harboring no other genetic anomalies besides the original oncogenic alteration. These results demonstrate the efficacy of ceritinib in the tumor regression of crizotinib-resistant \textit{ALK}+NSCLC patients, regardless of the various genetic mechanisms leading to crizotinib resistance.\textsuperscript{8}

As with crizotinib, patients treated with ceritinib also develop progression of disease. While ceritinib has been observed to overcome the resistance mutations L1196M, G1269A, S1206Y, and L1171T induced through crizotinib treatment, secondary mutations remain that are unable to be overcome by ceritinib. In a small study of 11 biopsied ceritinib-resistant tumors (two of the 11 obtained from different tumors in the same patient), five samples were found to harbor either F1174C or G1202R, two mutations that were also observed in crizotinib-resistant tumor samples. The patient who underwent biopsies at two different sites harbored two distinct resistance mutations, highlighting the inter-tumoral heterogeneity of resistance mechanisms.\textsuperscript{32} Better understanding of mechanisms of acquired ceritinib resistance is necessary to maximize the clinical efficacy of ceritinib in targeting \textit{ALK}+NSCLCs.

### Ceritinib in the treatment of brain metastases

In contrast to crizotinib, ceritinib has demonstrated clinical responses in untreated CNS metastases in both crizotinib-naïve and -resistant \textit{ALK}+NSCLC patients. In the ASCEND-1 study of 246 \textit{ALK}+NSCLC patients, 124 patients harboring brain metastases were treated with ceritinib. An ORR of 54.0% and a median PFS of 6.9 months were observed in these patients.\textsuperscript{36} Tumor response was seen in 50.0% of patients with brain metastases who received prior crizotinib compared to 69.2% of patients who were crizotinib naïve.\textsuperscript{36} Shaw et al also reported that 64 patients harboring \textit{ALK}+brain metastases

---

**Table 1 The most common adverse reactions observed in 255 \textit{ALK}+NSCLC patients treated with ≥400 mg daily ceritinib**

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Any grade (%)</th>
<th>Grades 3/4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>86</td>
<td>6</td>
</tr>
<tr>
<td>Anemia</td>
<td>84</td>
<td>5</td>
</tr>
<tr>
<td>Nausea</td>
<td>80</td>
<td>4</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>80</td>
<td>27</td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>75</td>
<td>13</td>
</tr>
<tr>
<td>Vomiting</td>
<td>60</td>
<td>4</td>
</tr>
<tr>
<td>Increased serum creatinine</td>
<td>58</td>
<td>2</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>54</td>
<td>2</td>
</tr>
<tr>
<td>Fatigue</td>
<td>52</td>
<td>5</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>49</td>
<td>13</td>
</tr>
<tr>
<td>Decreased phosphate</td>
<td>36</td>
<td>7</td>
</tr>
<tr>
<td>Anorexia</td>
<td>34</td>
<td>1</td>
</tr>
<tr>
<td>Constipation</td>
<td>29</td>
<td>0</td>
</tr>
<tr>
<td>GERD</td>
<td>16</td>
<td>1</td>
</tr>
</tbody>
</table>

**Note:** Data from Shaw et al.\textsuperscript{8} Novartis;\textsuperscript{37} and Kim et al.\textsuperscript{38}

**Abbreviations:** ALK, anaplastic lymphoma kinase; GERD, gastroesophageal reflux disease; NSCLC, non-small-cell lung cancer.
maintain a median PFS similar to 50 patients harboring only systemic tumors (6.9 months vs 7.0 months, with all patients receiving >400 mg of ceritinib daily).8

It appears that ceritinib has a tentative advantage over crizotinib regarding antitumor activity in ALK+–NSCLC patients with brain metastases. While its penetration mechanism remains unknown, its capacity to cross the blood–brain barrier and offer tumor shrinkage in the CNS marks a significant milestone in the treatment of ALK+–NSCLC patients.

Future perspectives
Success with crizotinib in the treatment of ALK+–NSCLC patients has instigated continuous research and development of more potent ALK inhibitors. Ceritinib has demonstrated efficacy in the treatment of ALK+–NSCLC in both crizotinib-naïve and crizotinib-refractory patients. In addition, there are several ongoing trials as well as scheduled trials further investigating ceritinib (see Table 2 for details).

With the EML4–ALK fusion gene accounting for only 3%–7% of NSCLC patients, the method of precisely determining ALK positivity in tumors is a crucial step in the treatment of patients harboring ALK+ tumors. While FISH is currently the primary mechanism for ALK+ detection, investigations into more cost-effective and accurate diagnostic tests could pave the road for improvements in the molecular identification of ALK positivity as well as the acquired resistance mechanisms resulting from TKI treatment.

There are other novel ALK inhibitors under development that have significantly demonstrated antitumor activity in advanced ALK+–NSCLC patients. The novel inhibitor alectinib is one such ALK inhibitor. In an ongoing Phase II study of 46 patients, 43 (93.5%) of them achieved overall responses (two complete, 41 partial response) with only mild reportable side effects.37 Alectinib also demonstrated significant anti-tumor response in CNS.38 Optimal treatment strategies for ALK+ NSCLC will continue to evolve with further investigations.

Finally, combination therapy involving ALK inhibitors and immune checkpoint inhibitors such as nivolumab, an anti-PD1 antibody that is currently approved for melanoma and squamous cell carcinoma of lung, may result in more effective and prolonged anti-tumor responses by optimizing anti-tumor T-cell responses. The study of safety and efficacy of ceritinib in combination with nivolumab in patients with ALK-positive NSCLC is being planned (NCT02393625).

### Table 2 Current list of ongoing trials of ceritinib (LDK378)

<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Trial Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02040870</td>
<td>a single-arm, Phase III study testing tolerance, efficacy, and pharmacokinetics of ceritinib in 100 Chinese adult patients with ALK+–NSCLC who are intolerant of crizotinib treatment</td>
</tr>
<tr>
<td>NCT02321501</td>
<td>a Phase I/Ib dose escalation and biomarker study of ceritinib (LDK378) and everolimus for locally advanced or metastatic solid tumors with an expansion in NSCLC characterized by abnormalities in ALK expression</td>
</tr>
<tr>
<td>NCT01950481</td>
<td>a Phase I study designed to determine the safety, efficacy, and pharmacokinetics of ceritinib (750 mg daily) in patients with impaired and nonimpaired hepatic function</td>
</tr>
<tr>
<td>NCT01634763</td>
<td>a Phase I study designed to determine the MTD of ceritinib as a single agent in Japanese ALK+–NSCLC patients</td>
</tr>
<tr>
<td>NCT01772797</td>
<td>a Phase Ib study designed to determine the MTD of ceritinib (750 mg daily) vs chemotherapy in patients already treated with platinum doublets and crizotinib</td>
</tr>
<tr>
<td>NCT02227602</td>
<td>a Phase II, open-label, multiple arm study of AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced NSCLC</td>
</tr>
<tr>
<td>NCT01742286</td>
<td>a Phase I study determining the MTD of ceritinib as a single agent with and without food in pediatric patients harboring ALK+ tumors</td>
</tr>
<tr>
<td>NCT01947608</td>
<td>expanded treatment protocol with LDK378 in ALK(+) NSCLC</td>
</tr>
<tr>
<td>NCT01964157</td>
<td>a Phase II study investigating the antitumor activity and safety profile of ceritinib in patients harboring ROS1+–NSCLCs</td>
</tr>
<tr>
<td>NCT02186821</td>
<td>a modular Phase II study to link targeted therapy to patients with pathway activated tumors: module – 7, ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1</td>
</tr>
<tr>
<td>NCT02227940</td>
<td>a Phase I trial investigating ceritinib and combination chemotherapy in treating patients with advanced solid tumors or locally advanced or metastatic pancreatic cancer</td>
</tr>
<tr>
<td>NCT02289144</td>
<td>an open-label, multicenter Phase II study evaluating the anti-tumor activity of ceritinib (750 mg daily) against metastatic, anaplastic thyroid cancers</td>
</tr>
<tr>
<td>NCT02292550</td>
<td>a Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive NSCLC</td>
</tr>
<tr>
<td>NCT02299505</td>
<td>a Phase I study of lower doses of ceritinib taken with a low-fat meal vs 750 mg of ceritinib in the fasted state in adult patients with (ALK-positive) metastatic NSCLC</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALK, anaplastic lymphoma kinase; NSCLC, non-small-cell lung cancer; MTD, maximum tolerated dose.

### Conclusion
In the recent past, tyrosine kinases have become an important area of cancer research, both in the understanding of their role in malignant growth pathways and the mechanisms necessary to inhibit their oncogenic activities in cancer patients. The ALK is one such target, having been identified as an oncogenic driver in a small subset (3%–7%) of
NSCLC. The advent of molecularly targeted therapies for NSCLCs has allowed for significantly improved clinical outcomes in \textit{ALK}+ patients. After limitations concerning treatment with the first-generation TKI crizotinib surfaced, ceritinib received Food and Drug Administration approval in April 2014 for treating crizotinib-resistant \textit{ALK}+-NSCLC patients. Ceritinib appears to be a potent successor to the first-generation TKI crizotinib in its ability to suppress untreated \textit{ALK}+ tumors as well as tumors harboring resistance mutations that render crizotinib ineffective. Several trials are currently underway.

**Disclosure**

The authors indicated no conflicts of interest in this work.

**References**


